- Home
- MBRX vs GLMD Comparison
MBRX vs GLMD Comparison
Compare MBRX & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- GLMD
- Stock Information
- Founded
- MBRX 2015
- GLMD 2000
- Country
- MBRX United States
- GLMD Israel
- Employees
- MBRX N/A
- GLMD N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- GLMD Health Care
- Exchange
- MBRX Nasdaq
- GLMD Nasdaq
- Market Cap
- MBRX 4.4M
- GLMD 4.5M
- IPO Year
- MBRX 2016
- GLMD 2014
- Fundamental
- Price
- MBRX $0.84
- GLMD $1.40
- Analyst Decision
- MBRX Strong Buy
- GLMD
- Analyst Count
- MBRX 3
- GLMD 0
- Target Price
- MBRX $17.33
- GLMD N/A
- AVG Volume (30 Days)
- MBRX 651.2K
- GLMD 2.6M
- Earning Date
- MBRX 05-09-2025
- GLMD 05-29-2025
- Dividend Yield
- MBRX N/A
- GLMD N/A
- EPS Growth
- MBRX N/A
- GLMD N/A
- EPS
- MBRX N/A
- GLMD N/A
- Revenue
- MBRX N/A
- GLMD N/A
- Revenue This Year
- MBRX N/A
- GLMD N/A
- Revenue Next Year
- MBRX N/A
- GLMD N/A
- P/E Ratio
- MBRX N/A
- GLMD N/A
- Revenue Growth
- MBRX N/A
- GLMD N/A
- 52 Week Low
- MBRX $0.40
- GLMD $1.33
- 52 Week High
- MBRX $5.91
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- MBRX 36.19
- GLMD 33.38
- Support Level
- MBRX $0.92
- GLMD $1.33
- Resistance Level
- MBRX $1.04
- GLMD $1.55
- Average True Range (ATR)
- MBRX 0.10
- GLMD 0.33
- MACD
- MBRX -0.01
- GLMD -0.04
- Stochastic Oscillator
- MBRX 3.98
- GLMD 5.90
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.